©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
World J Gastroenterol. Mar 7, 2026; 32(9): 115131
Published online Mar 7, 2026. doi: 10.3748/wjg.v32.i9.115131
Published online Mar 7, 2026. doi: 10.3748/wjg.v32.i9.115131
Research progress of plant-derived chemical compounds for overcoming pancreatic cancer drug resistance
Jia-Qi Yu, Shen-Jie Yu, Yu-Zhe Xue, Xiao-Guang Wang, Jiaxing University Master Degree Cultivation Base, Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang Province, China
Jia-Qi Yu, Ling-Yu Hu, Xiao-Fang Fan, Zhao-Feng Gao, Xiao-Rong Liu, Xue-Song He, Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Jiaxing University, Jiaxing 314000, Zhejiang Province, China
Ya-Hui He, Hong-Kun Zhou, Department of Hepatobiliary Surgery, The Affiliated Hospital of Jiaxing University, Jiaxing 314000, Zhejiang Province, China
Xiao-Fang Yu, School of Medicine, Cancer Institute (Key Laboratory of Cancer Prevention and Intervention), Zhejiang University, Hangzhou 310012, Zhejiang Province, China
Wei Chen, Cancer Institute of Integrated Traditional Chinese and Western Medicine, Key Laboratory of Cancer Prevention and Therapy Combining Traditional Chinese and Western Medicine of Zhejiang Province, Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province, Hangzhou 310012, Zhejiang Province, China
Co-first authors: Jia-Qi Yu and Shen-Jie Yu.
Co-corresponding authors: Xue-Song He and Xiao-Guang Wang.
Author contributions: Yu JQ, Yu SJ, He YH, Xue YZ, Yu XF, Chen W, Hu LY, Fan XF, Gao ZF, Zhou HK, Liu XR, He XS, and Wang XG contributed to the conceptualization; Yu JQ, Yu SJ, He XS, and Wang XG contributed to the literature search, writing-original draft and writing-review & editing; Yu JQ and Yu SJ contributed to the visualization; Liu XR, He XS, and Wang XG contributed to the supervision. Because of their outstanding contributions to this article, Yu SJ is hereby designated as the co-first author, and Wang XG is designated as the co-corresponding author.
Supported by the Key R&D Program of Zhejiang Province, No. 2024C03062; Project of the Bureau of Science and Technology of Jiaxing City, No. 2024AZ30002; Natural Science Foundation of Zhejiang Province, No. LBY23H200001; the Project of Zhejiang Provincial Medical and Health Research, No. 2023KY1212; and Starlit South Lake Leading Elite Program, No. 2023A400006.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Xue-Song He, PhD, Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Jiaxing University, No. 397 Huancheng North Road, Jiaxing 314000, Zhejiang Province, China. hexuesong2007@163.com
Received: October 14, 2025
Revised: November 11, 2025
Accepted: January 8, 2026
Published online: March 7, 2026
Processing time: 139 Days and 17.1 Hours
Revised: November 11, 2025
Accepted: January 8, 2026
Published online: March 7, 2026
Processing time: 139 Days and 17.1 Hours
Core Tip
Core Tip: This review summarizes recent research on the role of plant-derived compounds in overcoming drug resistance in pancreatic cancer. It provides insights into the mechanisms of resistance and highlights the potential of plant-based compounds as alternative therapeutic strategies. Considering the limitations of current therapies and the growing issue of drug resistance, plant-derived compounds offer a promising direction for enhancing treatment outcomes. This review aims to inform future research and contribute to the development of more effective, safer, and patient-friendly treatment options for pancreatic cancer.